Artificial intelligence (AI) software developer Imbio said that its chest CT image analysis software will be available on the Nuance AI Marketplace.
Imbio's Lung Density Analysis software, which has received U.S. Food and Drug Administration (FDA) clearance, quantifies lung regions with abnormal tissue density and generates visual maps of patients' lungs. Imbio's Lung Texture Analysis software for detecting texture abnormalities is currently pending FDA clearance, the firm said.
